Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment. - Wikidata - wikimedia - TriplyDB

Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.

Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.

http://www.wikidata.org/entity/Q37468480

about

Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study.Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes.Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.Pharmacological treatment of diabetes in older people.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.

P2860

Q31025919-D12B1869-DB16-462C-BCB0-1743F058DBF3 Q33779315-79D6D8DA-20AD-4C3A-B7D1-2229A6DFA264 Q33785141-B6714B7E-315A-4140-AE1A-810DED898AFD Q35841565-B07E08FB-6974-4E96-8BE9-6BD31E42E233 Q38189114-6CF251EE-7C65-4AD4-9DB5-C0DB7FF41306 Q38215452-EF16A8BF-A75A-4A38-9BF7-6B034EC3324B Q38235153-9A9E8AF8-7255-49D0-AD5A-54F73979D7A5 Q38266290-B13C0826-6424-4B72-989C-804CB151A6C2 Q38335751-40190E77-B294-40A0-B65A-2E4BB02890EA Q42676632-05445469-E85A-4F0C-A2C2-791B401796F3 Q51323275-80CEB850-7B35-4766-B5E6-9B06FB90039E

P2860

Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.

http://www.wikidata.org/entity/Q37468480

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Experience with vildagliptin i ...... te or severe renal impairment.

@en

Experience with vildagliptin i ...... te or severe renal impairment.

@nl

type

label

Experience with vildagliptin i ...... te or severe renal impairment.

@en

Experience with vildagliptin i ...... te or severe renal impairment.

@nl

prefLabel

Experience with vildagliptin i ...... te or severe renal impairment.

@en

Experience with vildagliptin i ...... te or severe renal impairment.

@nl

P1433

Q37468480-ECD4BE79-7B9E-4D29-A3C7-DD45037D1996

P1476

Q37468480-5E07CA23-C8EF-4177-B69C-ACDE1C9589CE

P2093

Q37468480-24E1C5F6-E10C-4A2A-BAFE-974847321957

Q37468480-F705FCEB-C54F-475B-9E65-62FF12A659FA

P2860

Q37468480-02D698A9-2D0A-4B27-904E-3417DBF1CF4D

Q37468480-0CE4A44C-7BCC-42E4-9290-631E022F180B

Q37468480-11160512-2028-4B8E-AB4D-4FAE8C10F320

Q37468480-12095355-99DF-441D-AE16-D1ECDBC20DF3

Q37468480-319BD5C7-0F71-4846-AFA2-DEEB84983B75

Q37468480-46697E64-5A48-4BD2-9775-CE21AE745824

Q37468480-4D881122-E6AF-416A-B948-F087E1D3AB98

Q37468480-52CFF47D-2F23-40D8-B42C-EFA84A8CA2F5

Q37468480-5FA930FA-717A-4046-A544-6D348C237A9A

Q37468480-62227738-34DE-486A-A0F3-3197B46F4B8A

P2888

Q37468480-811654F2-EBE4-436B-9F8E-65C4A05F90D9

P304

Q37468480-E5E10345-D339-48D5-A21D-8C10CCE1F83B

P31

Q37468480-FD84D233-DD67-4827-ACDA-0FEE896DA181

P356

Q37468480-3EDA0654-D654-4F72-BFA0-3F8E24780610

P433

Q37468480-A481AECD-A0BB-4913-97C1-A5FC4B3EE34D

P478

Q37468480-BD35BD55-A7BE-4125-9303-21DF96B88881

P577

Q37468480-E306267C-194F-465B-AC0D-6581B724953D

P5875

Q37468480-E51AEDBB-F613-4BD4-83A2-274D1FF14946

P698

Q37468480-0D75045D-1A07-4A60-8C57-B8E738B405E0

P921

Q37468480-1A1829F6-70BA-4E0C-905C-8C3C00C34C95

P932

Q37468480-34C699AF-A470-4B16-8D52-3DF9DDC3CA03

P356

S13300-013-0027-X

P1433

Diabetes Therapy

P1476

Experience with vildagliptin i ...... te or severe renal impairment.

@en

P2093

Anja Schweizer

http://www.w3.org/2001/XMLSchema#string

Sylvie Dejager

http://www.w3.org/2001/XMLSchema#string

P2860

Renal gluconeogenesis: its importance in human glucose homeostasis.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

Clinical practice. Nephropathy in patients with type 2 diabetes.

Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.

Diabetic nephropathy in the elderly.

Frequency of hypoglycemia and its significance in chronic kidney disease.

Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes.

Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.

P2888

s13300-013-0027-x

P304

257-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-013-0027-X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244992558

http://www.w3.org/2001/XMLSchema#string

P698

23821355

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3889331

http://www.w3.org/2001/XMLSchema#string